All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

How to treat patients with high-risk multiple myeloma

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma (MM) Hub spoke to Jesús San Miguel, University of Navarra, Pamplona, ES about the management of patients with high-risk MM.

Despite emerging treatments for patients with MM, the prognosis of patients with high-risk cytogenetics remains inferior to those with standard-risk disease. Could early intervention with novel therapies, such as CAR T-cell therapy and bispecific antibodies, improve the outcomes of patients with high-risk MM?

In this interview, Jesús San Miguel discusses the safety and efficacy of the B-cell maturation antigen-targeted CAR T-cell therapy, idecabtagene vicleucel (ide-cel; bb2121), in patients with relapsed/refractory MM.


Subscribe to get the best content related to multiple myeloma delivered to your inbox